Skip to Main Content

Key insight: Several biotech firms, including BrainStorm, AB Science, and Neuraltus, are forging ahead with drugs to treat aspects of ALS. Scientists are hopeful — but cautious.

Considering it took more than two decades for a second ALS drug to make it to the US market, you might think that few companies are willing to take the risk of developing such treatments.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


Comments are closed.